AN ELECTIVE SPECIALIST (GANODERIC ACID) FOR THE THERAPY OF ADVANCED PROSTATE CANCER

Pharmaceutics

In the Western world, prostate cancer is the most frequently diagnosed cancer in men and is responsible for significant morbidity and mortality. While conventional treatments are effective in eradicating cancer in its early stages, they frequently fail to treat metastatic disease in its later stages. As a result, alleviating the disease and enhancing patient outcomes necessitate the development of an efficient treatment that targets metastasis and growth of prostate tumors.Recent research has focused on natural extracts, particularly those with lower cellular toxicity to healthy tissue.Gano- deric acid, an extract from the Ganoderma lucidum mushroom that has been tested in multiple cancer models, is the subject of our discussion in this review as one potential candidate. Intriguingly, in late-stage metastatic disease, ganoderic acid DM (GA-DM) has been shown to be toxic to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis. The current understanding of this GA-DM extract and its potential use in the treatment of advanced prostate cancer will be discussed in this review.In addition, we will discuss the nanoparticle-based targeted delivery of GA-DM, which has the potential to reduce the toxicity of bystanders and increase the drug's efficacy. Natural chemotherapeutics, particularly those used to treat advanced prostate cancer, will advance as a result of a better understanding of this drug and its applications.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.